<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262585</url>
  </required_header>
  <id_info>
    <org_study_id>502.417</org_study_id>
    <nct_id>NCT02262585</nct_id>
  </id_info>
  <brief_title>Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers</brief_title>
  <official_title>Bioequivalence Study of BIBR 277 Tablet (Mannitol Based) Compared With Its Capsule Formation in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the bioequivalence of BIBR 277 tablet (Mannitol based) vs. BIBR 277
      capsule
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration of the Telmisartan in plasma)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72hr (area under the concentration-time curve of the Telmisartan in plasma from zero time to 72hr</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual time courses of the Telmisartan plasma concentrations</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time to reach Cmax)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the Telmisartan in plasma)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞(area under the concentration-time curve of Telmisartan in plasma from zero time to infinity)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT0-∞ (total mean residence time of Telmisartan molecules in the body)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in vital signs</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
    <description>blood pressure, pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in ECG</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBR 277 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Mannitol based)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 277 capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 277 tablet</intervention_name>
    <arm_group_label>BIBR 277 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 277 capsule</intervention_name>
    <arm_group_label>BIBR 277 capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;= 20 and &lt;= 35 years

          2. Weight: BMI &gt; 17.6 and &lt; 26.4 (Weight (kg) / Height (m)2)

          3. Subjects judged by the investigator to be eligible as study subjects, with no
             clinically significant findings after screening

          4. Subjects who volunteer to participate and are able to fully understand and agree with
             this study by written informed consent

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          3. Chronic or relevant acute infections

          4. History of hepatic disorder (e.g., biliary cirrhosis, cholestasis)

          5. History of serious renal disorder

          6. History of or present bilateral renal artery stenosis or lack of unilateral kidney
             accompanying arterial stenosis

          7. History of or present cerebrovascular disorder

          8. History of hyperkalemia

          9. History of hypersensitivity to active ingredient (Telmisartan) or other angiotensin II
             receptor antagonists

         10. History of or present orthostatic hypotension or faint

         11. Surgery of gastrointestinal tract (except appendectomy)

         12. History of alcohol or drug abuse

         13. Participation to another trial with an investigational drug within 4 months prior to
             the trial

         14. Whole blood donation more than 400 mL within 3 months prior to the trial

         15. Whole blood donation more than 100 mL within 1 month prior to the trial

         16. Donation of constituent of blood of more than 400 mL within 1 month prior to the trial

         17. Any medication which might influence the result of the trial within 10 days prior to
             the trial

         18. Excessive physical activities within 7 days prior to the trial

         19. Alcohol drinking within 3 days prior to the trial

         20. Inability to comply with restriction of protocol

         21. Other than above, those who are judged by the investigator to be inappropriate as the
             subjects of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

